Phase 1 Study of Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
Latest Information Update: 07 May 2024
At a glance
- Drugs Niraparib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 07 May 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Dec 2020).
- 14 Oct 2019 Status changed from not yet recruiting to recruiting.
- 03 Apr 2019 New trial record